Transgene reports on oncolytic virus therapy

Transgene SA said that its in-licensed oncolytic virus therapy, JX-594, has shown a “mechanistic proof-of-concept” in an early clinical trial of patients with metastatic melanoma. The results of the trial have been reported in Molecular Therapy.